Pfizer Inc. (NYSE:PFE) Stock Holdings Lifted by IFM Investors Pty Ltd

IFM Investors Pty Ltd grew its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 8.3% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,178,399 shares of the biopharmaceutical company's stock after purchasing an additional 90,190 shares during the period. IFM Investors Pty Ltd's holdings in Pfizer were worth $29,861,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Beam Wealth Advisors Inc. increased its holdings in Pfizer by 1.5% in the fourth quarter. Beam Wealth Advisors Inc. now owns 27,444 shares of the biopharmaceutical company's stock valued at $728,000 after buying an additional 401 shares during the last quarter. Providence Capital Advisors LLC raised its position in shares of Pfizer by 0.4% during the 4th quarter. Providence Capital Advisors LLC now owns 114,358 shares of the biopharmaceutical company's stock valued at $3,034,000 after acquiring an additional 409 shares in the last quarter. Donaldson Capital Management LLC lifted its stake in Pfizer by 1.2% during the fourth quarter. Donaldson Capital Management LLC now owns 35,694 shares of the biopharmaceutical company's stock worth $947,000 after purchasing an additional 410 shares during the last quarter. William B. Walkup & Associates Inc. boosted its holdings in Pfizer by 1.2% in the fourth quarter. William B. Walkup & Associates Inc. now owns 39,368 shares of the biopharmaceutical company's stock worth $1,044,000 after purchasing an additional 454 shares during the period. Finally, Balboa Wealth Partners increased its stake in Pfizer by 1.6% during the fourth quarter. Balboa Wealth Partners now owns 30,678 shares of the biopharmaceutical company's stock valued at $814,000 after purchasing an additional 480 shares during the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Price Performance

Shares of PFE stock traded up $0.13 during midday trading on Friday, reaching $25.45. 27,104,580 shares of the company were exchanged, compared to its average volume of 41,625,077. The company's 50 day moving average price is $23.67 and its two-hundred day moving average price is $24.84. The company has a market cap of $144.66 billion, a P/E ratio of 18.44, a PEG ratio of 0.92 and a beta of 0.58. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $31.54. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.96 and a current ratio of 1.26.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The firm had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. During the same quarter in the previous year, the business posted $0.82 earnings per share. The firm's quarterly revenue was down 7.8% compared to the same quarter last year. On average, sell-side analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.76%. The ex-dividend date is Friday, July 25th. Pfizer's dividend payout ratio (DPR) is presently 124.64%.

Wall Street Analyst Weigh In

PFE has been the topic of a number of recent research reports. BMO Capital Markets reduced their price target on shares of Pfizer from $36.00 to $30.00 in a research report on Thursday, April 17th. Bank of America raised their target price on shares of Pfizer from $26.00 to $27.00 and gave the stock a "neutral" rating in a report on Wednesday, April 30th. TD Cowen decreased their target price on Pfizer from $32.00 to $28.00 and set a "hold" rating for the company in a research note on Tuesday, April 22nd. Cantor Fitzgerald began coverage on Pfizer in a research report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 price target on the stock. Finally, Morgan Stanley boosted their price objective on Pfizer from $31.00 to $32.00 and gave the company an "equal weight" rating in a research report on Wednesday, April 30th. One research analyst has rated the stock with a sell rating, thirteen have issued a hold rating, six have assigned a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $28.55.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.